Thomas Freeburg was named Chief Financial Officer of Niki BioSolutions, Inc. As of November 6, 2026, Niki BioSolutions, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from September 4, 2026 to October 13, 2026, naming 1 appointment (Form 8-K, October 13, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Niki BioSolutions, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Niki BioSolutions, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-09-04 to 2026-10-13. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Niki BioSolutions, Inc. files it.
Also on the record for Niki BioSolutions, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 24, 2026 | Stake report, Schedule 13D, by Kira S. Sheinerman | 51.56% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Niki BioSolutions, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Niki BioSolutions, Inc. and the records around it.
Niki BioSolutions, Inc. elsewhere on the record
- 5%+ stake filings Jul 2026
- Who owns it
Watch Niki BioSolutions, Inc.
Get an email when Niki BioSolutions, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Niki BioSolutions, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Niki BioSolutions, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Niki BioSolutions, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-13 | In | Chief Financial Officer | 8-K, 2026-10-13 | ||
| 2026-09-04 | Reported | not named in the filing | 8-K, 2026-09-04 |
Who leads Niki BioSolutions, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Thomas Freeburg, appointed (filed 2026-10-13).
New leaders reset buying decisions — get the Full Report on Niki BioSolutions, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Niki BioSolutions, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Niki BioSolutions, Inc.Every change, in the filing's words
Appointed: Thomas Freeburg, Chief Financial Officer
On October 9, 2026, the Board of Directors (the "Board") of Niki BioSolutions, Inc., a Delaware corporation (the "Company"), appointed Thomas Freeburg as the Chief Financial Officer, to serve at the discretion of the Board, for a period of two years, commencing as of September 1, 2026, unless terminated sooner by either party.
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- Prior to his appointment, Mr. Freeburg, age 59, was the Managing Member of Cambridge Accounting Group, LLC from 2014 to September 2017 and April 2023 to August 2026.
- Mr. Freeburg was previously employed by Interpace Biosciences, Inc. (NASDAQ: IDXG) and served as the company's Chief Accounting Officer from October 2017 through January 2021, and as Chief Financial Officer, Secretary and Treasurer from February 2021 through March 2023.
- From 2009 to 2014, Mr. Freeburg served as the Director of SEC Reporting and Accounting Policies for Coach, Inc., which was the predecessor company to Tapestry, Inc. (NYSE: TPR).
- From 2006 to 2008, Mr. Freeburg served as the Director of External Reporting of Scholastic Corporation (NASDAQ: SCHL).
- Mr. Freeburg is a Certified Public Accountant and earned his Bachelor of Science degree in Public Accounting from Long Island University.
- Pursuant to the terms of the Employment Agreement between the Company and Mr. Freeburg, Mr. Freeburg will receive a base salary of $250,000, which shall be paid monthly although $25,000 shall be deferred until such time as the Company receives certain funding, as set forth in the Employment Agreement; his base salary shall increase to $275,000, upon the Company's receipt of additional funding.
Reported
On September 1, 2026, the Company entered into separate agreements with each of Mr. Huen and Mr. Mireskandari, each with an August 1, 2026 effective date.
- In connection with the previously announced merger transaction, Mr. Ian Huen and Alidad Mireskandari became the CEO and COO, respectively of Niki BioSolutions, Inc. (the "Company").
- Pursuant to the appointment letter for Mr. Huen (the "Huen Appointment letter"), Mr. Huen shall serve as the Company's Chief Executive Officer.
- The Huen Appointment letter has an initial term of six months, subject to renewal by mutual agreement.
- His monthly base salary is HKD 210,000, which is approximately USD26,800 based on an exchange rate of 7.84 as of the date of this Report.
- He may also be entitled to a discretionary bonus, subject to the discretion of the Board and approval of the Compensation Committee.
- In addition, Mr. Huen is eligible to receive share bonuses, with the amount, timing and vesting terms to be determined by the Company and approved by the Compensation Committee, and an option to purchase shares pursuant to the Company's Share Option Plan.
- Either Mr. Huen or the Company may terminate his appointment upon not less than one month's prior written notice, and the Company may terminate his appointment immediately upon the occurrence of certain specified events.
- Pursuant to the employment agreement with Mr. Mireskandari (the "Mireskandari Employment Agreement"), he will serve as President and Chief Operating Officer of the Company.
Tools for this story
Each opens in a new tab, filled in for Niki BioSolutions, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.